Pioglitazone and Gemfibrozil Interaction

Understanding the Pioglitazone and Gemfibrozil Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Pioglitazone belongs to the Thiazolidinedione class and Gemfibrozil belongs to the Fibrate class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Gemfibrozil blocks the liver enzyme that breaks down pioglitazone, which causes the drug to stay in your body longer and reach higher levels. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Pioglitazone has 10 total documented interactions on file in this dataset, and Gemfibrozil has 20. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should limit your pioglitazone dose to no more than 15 mg per day while you are taking gemfibrozil. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pioglitazone or Gemfibrozil based on a web page, speak with your prescriber or pharmacist before making any change.